-
Venclexta/Venclyxto improved overall survival in previously untreated AML patients
- March 26, 2020
- Posted by: PharmaScroll
- Category:
No Comments -
Post-HSCT Cyclophosphamide use Improves Transplantation Outcomes for AML/MDS
- March 22, 2020
- Posted by: PharmaScroll
- Category:
-
FDA approves Opdivo® + Yervoy® for HCC patients previously treated with sorafenib
- March 22, 2020
- Posted by: PharmaScroll
- Category:
-
Shire Announces Sale of Oncology Business to Servier for $2.4 Billion to Focus on Rare Disease Leadership
- April 18, 2018
- Posted by: PharmaScroll
- Category: